Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Adam H. Schechter reported a sale of 5,273 common shares on
The filing also lists restricted stock vesting events from the issuer on
LABCORP HOLDINGS INC.February 27, 2026, she sold 547.5397 shares at an average price of
LH Form 144 notice reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The excerpt lists 548 common shares with an aggregate value of $155,999.54, NYSE listing, and a filing date of
The entry shows restricted stock vesting activity on
LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, Chief Medical Officer and Chief Scientific Officer, reported an open-market sale of common stock. On February 24, 2026, he sold 1,500 shares at an average price of $286.305 per share.
After this transaction, Caveney directly owns 30,106.9234 shares of Labcorp common stock. This filing reflects an insider reducing his direct shareholdings through a routine open-market sale.
Labcorp Holdings Inc. details its 2025 operations, strategy, and risks in its annual report. The company generated
Dx focuses on routine and specialty testing, performing more than 750 million tests and serving about 175 million patient encounters through over 2,200 patient service centers and extensive digital tools, including AI‑enabled test selection. BLS supported roughly 85% of FDA drug and therapeutic approvals through global early development and central lab services.
Labcorp invested
LH filed a Form 144 reporting proposed sales of common stock tied to restricted stock vesting. The notice lists planned vesting-related dispositions including 458 shares vested 02/06/2025, 447 shares vested 02/07/2025, 66 shares vested 02/11/2025, and 529 shares vested 02/11/2026. The transactions are described as issuer restricted stock vesting.
LABCORP HOLDINGS INC.February 19, 2026, he sold 666 shares of Labcorp common stock at a price of $277.94 per share in a transaction coded as an open-market sale. After this sale, he directly owns 1,852.2194 shares of Labcorp common stock. The transaction was executed under a pre-established trading plan adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
Labcorp Holdings Inc. reported solid growth for 2025 and issued an upbeat 2026 outlook. Revenue rose to $13.95 billion from $13.01 billion, while diluted EPS increased to $10.46 from $8.84 and adjusted EPS climbed to $16.44 from $14.57. Free cash flow improved to $1.21 billion from $1.10 billion.
In the fourth quarter, revenue reached $3.52 billion with adjusted EPS of $4.07, supported by margin expansion in Diagnostics and Biopharma Laboratory Services. For 2026, Labcorp guides to enterprise revenue growth of 4.7%–6.0%, adjusted EPS of $17.55–$18.25, and free cash flow of $1.24–$1.36 billion. The company invested heavily in acquisitions, new specialty tests, and a planned 500,000 square foot central lab facility, while returning cash through $0.72 per-share dividends and $450 million of share repurchases.
Labcorp Holdings Inc. executive Amy B. Summy reported equity compensation activity involving Restricted Stock Units and common stock. On February 11, 2026, 230 Restricted Stock Units were exercised into 230 shares of Labcorp common stock at an exercise price of $0, increasing her directly held common shares to 5,804.5.
On the same date, 83 shares of common stock were automatically withheld at a price of $289.89 per share to cover tax withholding obligations, leaving her with 5,721.5 directly owned shares. The RSUs were part of a grant vesting in three equal annual installments beginning on February 11, 2026, and she held 1,304 Restricted Stock Units after these transactions.
Wilkinson Peter J reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 1,598 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 2,128 shares.